Bristol Myers Squibb has exercised an option on an immune-modulating drug candidate developed by UK artificial intelligence specialist Exscientia, paying $20 million for the buy-in as part
Akili already has the first and only FDA cleared video game-based digital therapeutic (DTx) for children with attention-deficit hyperactivity disorder (ADHD), but is looking to add to its r
Artificial intelligence (AI) specialist XtalPi has chalked up a second big financing in the space of a year, raising $400 million and taking its valuation to around $2 billion.
Researchers in the UK are asking adults who have taken a COVID-19 test in the last 72 hours to record themselves coughing, breathing and speaking to help develop new ways to detect infectio